Research Article: Active implant combining human stem cell microtissues and growth factors for bone-regenerative nanomedicine

Nanobiomaterials are also increasingly being recognized for their significant potential in targeted delivery of drug payloads, and particularly for drug delivery to inaccessible anatomical or intracellular compartments. This is indicated in an original article in the Special Focus Issue ‘Engineering the nanoenvironment for regenerative medicine’ by Schiavi et al., who present research on a new generation of collagen nanofiber implants functionalized with BMP-7 nanoreservoirs and equipped with human mesenchymal stem cell microtissues for regenerative nanomedicine.

Go to the profile of Nanomedicine
Apr 01, 2015
0
0

Aims: Mesenchymal stem cells (MSCs) from adult bone marrow provide an exciting and promising stem cell population for the repair of bone in skeletal diseases. Here, we describe a new generation of collagen nanofiber implant functionalized with growth factor BMP-7 nanoreservoirs and equipped with human MSC microtissues (MTs) for regenerative nanomedicine. Materials & methods: By using a 3D nanofibrous collagen membrane and by adding MTs rather than single cells, we optimize the microenvironment for cell colonization, differentiation and growth. Results & conclusion: Furthermore, in this study, we have shown that by combining BMP-7 with these MSC MTs in this double 3D environment, we further accelerate bone growth in vivo. The strategy described here should enhance the efficiency of therapeutic implants compared with current simplistic approaches used in the clinic today based on collagen implants soaked in bone morphogenic proteins.

Please visit Nanomedicine online to view the article.

Nanomedicine is also on Twitter: follow us @fsgnnm now!

Author affiliations:

Jessica Schiavi

INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France

Laetitia Keller

INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France

David-Nicolas Morand

INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France

Natalia De Isla

Hôpital Central, Service de Chirurgie Orthopédique & UMR CNRS 7365 IMOPA, Nancy, France

Olivier Huck

INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France

Jean Christophe Lutz

INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France

Didier Mainard

Hôpital Central, Service de Chirurgie Orthopédique & UMR CNRS 7365 IMOPA, Nancy, France

Pascale Schwinté

INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France

Nadia Benkirane-Jessel

INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France

Go to the profile of Nanomedicine

Nanomedicine

Journal, Future Science Group

Nanomedicine (Impact Factor: 4.889 [2015]), is an award-winning peer-reviewed journal from Future Science Group, available in both print and online formats. Published 24 times per year, Nanomedicine is a uniquely medicine-focused journal, addressing the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats. Nanomedicine is listed by Medline/PubMed, Science Citation Index Expanded, Journal Citation Reports/Science Edition, Current Contents/Life Sciences and the Biotechnology Citation Index. Professor Kostas Kostarelos (Nanomedicine Lab, University of Manchester, UK) and Professor Charles R Martin (University of Florida, FL, USA) are the journal’s Senior Editors. You can find out more about Nanomedicine on our website (http://www.futuremedicine.com/loi/nnm), including the journal’s aims and scope and details of our international editorial board.

No comments yet.